netFormulary NHS
Dorset
The Dorset Formulary has been developed in associations with
NHS Dorset Clinical Commissioning Group
Dorset County Hospital NHS Foundation Trust
Dorset Healthcare University NHS Foundation Trust
University Hospitals Dorset NHS Foundation Trust
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

Updated in accordance with CDF and NICE guidance May 2018. For latest CDF list click here.

Chapter Links...
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
08.01.05  Expand sub section  CDK inhibitors
08.01.05  Expand sub section  Dacarbazine and Temozolomide
08.01.05  Expand sub section  Platinum compounds
08.01.05  Expand sub section  Protein kinase inhibitors to top
Cytotoxic Drug AbemaciclibBlack Triangle (Verzenios®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF in line with NICE TA563 and TA579 and CDF criteria.

 
Link  NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
 
Cytotoxic Drug AcalabrutinibBlack Triangle (Calquence®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned within the CDF as an option for untreated chronic lymphocytic leukaemia (CLL) in adults, only if:
  •  they have a 17p deletion or TP53 mutation

Commissioned within the CDF as a second-line option for treating CLL in adults where:
  •  ibrutinib is their only suitable treatment option

Commissioning will transfer to NHSE 90 days following NICE publication

 
 
Cytotoxic Drug AfatinibBlack Triangle (Giotrif®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Commissioned by NHS England in line with NICE TA310.

 
Link  NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
 
Cytotoxic Drug AlectinibBlack Triangle (Alecensa®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA536 recommendations.

 
Link  NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
 
Cytotoxic Drug Axitinib (Inlyta®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Commissioned by NHS England in line with NICE TA333.

 
Link  NICE TA 333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
 
Cytotoxic Drug BinimetinibBlack Triangle (Mektovi®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF in line with NICE TA562 and CDF criteria (in combination encorafenib).

 
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
 
Cytotoxic Drug BosutinibBlack Triangle (Bosulif®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA401.

 
Link  NICE TA401 Bosutinib for previously treated chronic myeloid leukaemia
 
Cytotoxic Drug BrigatinibBlack Triangle (Alunbrig®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA571 as monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer previously treated with crizotinib.

Commissioned by NHSE in line with NICE TA670 as an option for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) that has not been previously treated with an ALK inhibitor in adults.
  •  This indication is funded by CDF until 27th April 2021

 
Link  NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Link  NICE TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
 
Cytotoxic Drug CabozantinibBlack Triangle (Cometriq®, Cabometyx®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Cabometyx®:



  • Commissioned by NHSE in accordance with NICE TA463 and TA542 for the treatment of previously treated advanced renal cell carcinoma and untreated locally advanced or metastatic renal cell carcinoma respectively.

  • Patients initiated on the Named Patient Programme should remain on free of charge stock for the duration of their treatment.


Cometriq®:



  • Commissioned in accordance with NICE TA516 for the first line treatment of medullary thyroid cancer.

 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
 
Cytotoxic Drug CeritinibBlack Triangle (Zykadia®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA395 and TA500.

 
Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
 
Cytotoxic Drug CrizotinibBlack Triangle (Xalkori®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by CDF in line with CDF criteria and NICE TA529 and NHS England in line with NICE TA406 and TA422.

 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
 
Cytotoxic Drug DabrafenibBlack Triangle (Tafinlar®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Commissioned by NHS England in line with NICE TA321, TA396 and TA544.


BlueTeq TA396 and TA544 require BlueTeq prior approval.

 
Link  NICE TA:321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
 
Cytotoxic Drug Dacomitinib (Vizimpro®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

In accordance with NICE TA595

 
Link  NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
 
Cytotoxic Drug Dasatinib (Sprycel®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

Commissioned by NHS England in line with NICE TA425 and TA426.

 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
 
Cytotoxic Drug EncorafenibBlack Triangle (Braftovi®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by CDF in line with NICE TA562 and CDF criteria (in combination binimetinib).

Commissioned by NHSE in combination with Cetuximab as an option for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment in line with NICE TA668.
  •  NOTE: Interim funding is via the CDF until April 6th 2021

 

 
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Link  NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
 
Cytotoxic Drug EntrectinibBlack Triangle (Rozlytrek®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA643 for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.

Commissioned via the Cancer Drugs Fund (CDF) in line with NICE TA644 for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children 12 years and older if:
   • the disease is locally advanced or metastatic or surgery could cause severe health problems and
   • they have not had an NTRK-inhibitor before and
   • they have no satisfactory treatment options.

 
Link  NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
Link  NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours
 
Cytotoxic Drug Erlotinib (Tarceva®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England for cancer, policy in progress. See NICE TA162 and TA374. 
Link  NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Link  NICE374: Erlotinib and Gefitinib for the treatment of non-small-cell lung cancer that has progressed after prior chemotherapy (previously TA162)
Link  NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (not recommended)
 
Cytotoxic Drug Everolimus (Afinitor®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

Commissioned by NHS England in line with NICE TA recommendations.

 
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
 
Cytotoxic Drug Gefitinib (Iressa®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England in line with TA192. 
Link  NICE TA192: gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell-lung cancer
Link  NICE TA374: Gefitinib and erlotinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (previously TA175) (not recommended)
 
Cytotoxic Drug GilteritinibBlack Triangle (Xospata®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA642 as monotherapy for treating relapsed or refractory FLT3‑mutation-positive acute myeloid leukaemia (AML) in adults.

Gilteritinib should not be given as maintenance therapy after a haematopoietic stem cell transplant.

 
Link  NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
 
Cytotoxic Drug Ibrutinib (Imbruvica® )
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

In accordance with CDF policy and NICE TA429, TA491 and TA502.

 
Link  NICE TA429:Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
 
Cytotoxic Drug IdelalisibBlack Triangle (Zydelig® )
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Commissioned in accordance with NICE TA359.


 

 
Link  NICE TA 359: Idelalisib for treating chronic lymphocytic leukaemia
Link  NICE TA 469: Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)
 
Cytotoxic Drug Imatinib (Generic, Glivec®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

For haematology indications use generic drug, for gastrointestinal stromal tumours use Glivec® brand.

 
Link  NICE TA70: guidance on the use of imatinib for chronic myeloid leukaemia
Link  NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (Previously NICETA196)
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
 
Cytotoxic Drug LarotrectinibBlack Triangle (Vitrakvi®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned in line with CDF criteria and conditions of the managed access agreement in accordance with the recommendations in NICE TA630 for treating NTRK fusion-positive solid tumours.

 
Link  NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours
 
Cytotoxic Drug LenvatinibBlack Triangle (Kisplyx®, Lenvima®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Kisplyx®:



  • Commissioned by NHSE in accordance with NICE TA498 for the treatment of previously treated renal cell carcinoma in combination with everolimus.


Lenvima®:



  • Commissioned by NHSE in accordance with NICE TA535 for the treatment of differentiated thyroid cancer after radioactive iodine.

  • Commissioned by NHSE in accordance with NICE TA551 for first line treatment of Child Pugh A locally advanced or metastatic hepatocellular carcinoma.

 
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Link  NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
 
MidostaurinBlack Triangle (Rydapt®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA523 recommendations.

 
Link  NICE TA523: Midostaurin for untreated acute myeloid leukaemia
 
Neratinib (Nerlynx®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with the recommendations in NICE TA612.

 
Link  NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
 
Cytotoxic Drug Nilotinib (Tasigna®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

Commissioned by NHS England in line with NICE TA241 and TA251.

 
Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
 
Cytotoxic Drug Nintedanib Black Triangle (Vargatef®, Ofev®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Vargatef®:



  • Commissioned by NHS England in line with NICE TA347 for non-small-cell lung cancer.


Restricted Item Ofev®: 



  • Commissioned by NHS England in line with NICE TA379 for idiopathic pulmonary fibrosis via specialist centres only.

 
Link  NICE TA 347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Link  NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
 
Cytotoxic Drug OsimertinibBlack Triangle (Tagrisso®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE for treating EGFR T790M mutation-positive advanced or metastatic non-small-cell lung cancer (NSCLC) in adults in accordance with NICE TA653, only if their disease has progressed after first-line treatment with an EGFR tyrosine kinase inhibitor.

Commissioned by NHSE for untreated EGFR mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults in accordance with NICE TA654.

 
Link  NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
Link  NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
 
Cytotoxic Drug PalbociclibBlack Triangle (IBRANCE®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned in accordance with NICE TA495 for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.


Patients inititated on the free of charge patient access programme should continue on free of charge treatment so long as they derive benefit.


Commissioned by CDF in line with NICE TA619 for treating hormone receptor-positive, HER2-negative, advanced breast cancer in combination with Fulvestrant.

 
Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
 
Cytotoxic Drug Pazopanib (Votrient®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England as per NICE TA215. 
Link  NICE TA215: pazopanib for the first line treatment of advanced renal cell carcinoma
 
PemigatinibBlack Triangle (Pemazyre®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Available under EAMS for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy

 
 
Cytotoxic Drug PonatinibBlack Triangle (Iclusig®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA451.

 
Link  DSU vol 8, iss 4, Nov 2014: S2. Ponatinib (Iclusig): risk of vascular occlusive events
Link  NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
 
Cytotoxic Drug RegorafenibBlack Triangle (Stivarga® )
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA488 and TA555.

 
Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Link  NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
 
Cytotoxic Drug RibociclibBlack Triangle (Kisqali®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned in accordance with NICE TA496 for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.

Commissioned by the CDF in accordance with NICE TA687 for treating hormone receptor-positive, (HER2)-negative, locally advanced or metastatic breast cancer in adults  
- This indication will transition to NHSE on 29th June 2021

 
Link  NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA687: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
 
Cytotoxic Drug Ruxolitinib (Jakavi®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA386.
BlueTeq is required for this indication from 16/12/2020

 

 
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
 
Cytotoxic Drug Sorafenib (Nexavar®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA474 and by CDF as per NICE TA535 and CDF policy.

 
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
 
Cytotoxic Drug Sunitinib (Sutent®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine

For use in line with NICE TA169, TA179 and TA449.


BlueTeq Blueteq prior approval required for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin with disease progression (TA449).

 
Link  NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA178: Renal cell carcinoma (2nd line - not recommended)
 
Cytotoxic Drug TivozanibBlack Triangle (Fotivda®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in accordance with NICE TA512.

 
Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
 
Cytotoxic Drug TrametinibBlack Triangle (Mekinist®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA396.


Commissioned by |CDF in line with CDF criteria and NICE TA544.

 
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
 
Cytotoxic Drug Vemurafenib (Zelboraf®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England in line with NICE TA269. 
Link  NICE TA269: vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
 
08.01.05  Expand sub section  Taxanes
08.01.05  Expand sub section  Topoisomerase I inhibitors
08.01.05  Expand sub section  Monoclonal antibodies
 ....
 Non Formulary Items
Cytotoxic Drug  Afatinib  (Giotrif®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
Not recommended by NICE TA 444 for locally advanced or metastatic squamous non-small-cell lung cancer after platinum-based chemotherapy
Link  NICE TA 444 Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
Link  NICE TA 452: Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)
Cytotoxic Drug  Alectinib

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
High Cost Medicine

Not recommended for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in accordance with NICE TA438

Link  NICE TA438: Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)
Cytotoxic Drug  Bosutinib Black Triangle  (Bosulif®)

View adult BNF View SPC online Track Changes
Non Formulary
Black
High Cost Medicine

Not recommended by NICE TA576 for untreated chronic myeloid leukaemia.

Link  NICE TA576: Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)
Cytotoxic Drug  Cabozantinib Black Triangle  (Cometriq®)

View adult BNF View SPC online Track Changes
Non Formulary
Black
High Cost Medicine
NHS England

Not recommended in accordance with NICE TA582

Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Cytotoxic Drug  Cobimetinib hemifumarate  (Cotellic®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
High Cost Medicine
Not recommended by NICE TA414 for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Link  NICE TA582:Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal)
Cytotoxic Drug  Dabrafenib Black Triangle  (Tafinlar®)

View adult BNF View SPC online Track Changes
Non Formulary
Black
High Cost Medicine

Not recommended with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer as per NICE TA564.

Link  NICE TA564: Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)
Cytotoxic Drug  Everolimus  (Votubia®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
High Cost Medicine
Commissioned by NHS England via specialist centres only for:
  • renal angiomyolipoma associated with tubular sclerosis
  • subependymal giantcell astrocytoma (SEGA) associated with tuberous sclerosis complex
  • Link  Clinical Commissioning Policy 16066/P: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
    Link  Clinical Commissioning Policy Statement B14X09: Everolimus for treatment of angiomyolipomas associated with tuberous sclerosis
    Cytotoxic Drug  Ibrutinib  (Imbruvica® )

    View adult BNF View SPC online Track Changes
    Non Formulary
    Black
    High Cost Medicine

    In accordance with NICE TA437, TA452 and T608.

    Link  NICE TA437: Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy
    Link  NICE TA452: Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)
    Link  NICE TA608: Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal)
    Cytotoxic Drug  Idelalisib Black Triangle  (Zydelig® )

    View adult BNF View SPC online Track Changes
    Non Formulary
    Black
    High Cost Medicine
    NHS England

    Not commissioned in combination with ofatumumab in accordance with as per NICE TA469 or for treating refractory follicular lymphoma as per NICE 604

    Link  NICE TA604: Idelalisib for treating refractory follicular lymphoma
    Link  NICE TA 469: Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)
    Cytotoxic Drug  Lapatinib  (Tyverb®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    High Cost Medicine
    Not recommomended by NICE
    Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
    Cytotoxic Drug  Sorafenib

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black

    Not recommended as first or second line for advanced/metastatic renal cell cancer (as in NICE TA178).


    Also not recommended in the treatment of advanced hepatocellular cancer with Child-Pugh gradeB liver impairment (NICE TA474).

    Cytotoxic Drug  Temsirolimus  (Torisel®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    High Cost Medicine
    NICE do not recommended temsirolimus as a first drug treatments for people with advanced and/or metastatic renal cell carcinoma.
    Link  NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma (not recommended)
    Link  NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
    Cytotoxic Drug  Trametinib Black Triangle  (Mekinist®)

    View adult BNF View SPC online Track Changes
    Non Formulary
    Black
    High Cost Medicine

    Not recommended with dabrafenib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer as per NICE TA564.

    Link  NICE TA654: Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)
    Cytotoxic Drug  Vandetanib Black Triangle  (Caprelsa®)

    View adult BNF View SPC online Track Changes
    Non Formulary
    Black
    High Cost Medicine
    Cancer Drugs Fund

    In line with NICE TA550 from 11 February 2019 no new patients will be able to receive the drug for treating aggressive and symptomatic medullary thyroid cancer. However, existing patients, registered prior to this date and receiving the drug via CDF funding will continue to receive the drug funded by the CDF until they and their NHS clinician consider it appropriate to stop.

    Link  NICE TA550: Vandetanib for treating medullary thyroid cancer - not recommended
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to children's BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Green

    May be initiated, stabilised and maintained in primary, secondary or tertiary care  

    Amber

    Amber drug - without shared care  

    Amber SCG

    Amber drug - with shared care guideline  

    Red

    For secondary or tertiary care initiation and long-term maintenance of prescribing  

    Black

    Not recommended  

    netFormulary